We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Aduhelm Cost Concerns Grow as FDA Officials Defend the Agency’s Approval
Aduhelm Cost Concerns Grow as FDA Officials Defend the Agency’s Approval
The FDA’s approval of Biogen’s Aduhelm for treatment of Alzheimer’s disease (AD) has taken regulators, payers and patients to an unprecedented intersection of medical need, clinical benefit and cost.